Ascentage Pharma Grants RSUs and Share Options
Ticker: AAPG · Form: 6-K · Filed: Nov 28, 2025 · CIK: 2023311
Sentiment: neutral
Topics: equity-grant, RSU, stock-options
TL;DR
Ascentage Pharma just dropped more RSUs and options - watch for potential dilution.
AI Summary
Ascentage Pharma Group International announced on November 27, 2025, that it has made further grants of Restricted Stock Units (RSUs) under its 2022 RSU Scheme and has also granted options under its Post IPO Share Option Scheme. This filing is a Report of Foreign Private Issuer (Form 6-K) for the month of November 2025.
Why It Matters
This announcement relates to equity compensation for employees and executives, which can impact future share dilution and employee incentives.
Risk Assessment
Risk Level: low — The filing is a routine report of equity grants and does not indicate significant new risks.
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer of the report
- November 27, 2025 (date) — Date of the announcement
- 2022 RSU Scheme (scheme) — Plan under which RSUs were granted
- Post IPO Share Option Scheme (scheme) — Plan under which options were granted
FAQ
What type of equity awards were granted by Ascentage Pharma?
Ascentage Pharma granted further awards under the 2022 RSU Scheme and granted options under the Post IPO Share Option Scheme.
When was the announcement regarding these equity grants made?
The announcement was made on November 27, 2025.
What is the form type filed by Ascentage Pharma?
Ascentage Pharma filed a Form 6-K, Report of Foreign Private Issuer.
What is the principal executive office address of Ascentage Pharma?
The principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Does Ascentage Pharma file annual reports under Form 20-F or 40-F?
Ascentage Pharma indicated that it files annual reports under cover of Form 20-F.
Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-11-28 09:10:27
Filing Documents
- ea0267650-6k_ascentage.htm (6-K) — 11KB
- ea026765001ex99-1_ascentage.htm (EX-99.1) — 64KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001213900-25-115800.txt ( ) — 102KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On November 27, 2025, Ascentage Pharma Group International issued an announcement entitled “Further Grant Of Awards Under The 2022 RSU Scheme; And Grant Of Options Under The Post IPO Share Option Scheme”. A copy of the announcement is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Announcement dated November 27, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: November 28, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3